SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/77923"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/77923" > Aspirin and extende...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008195naa a2201093 4500
001oai:gup.ub.gu.se/77923
003SwePub
008240528s2008 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-81162
009oai:prod.swepub.kib.ki.se:117567180
0247 a https://gup.ub.gu.se/publication/779232 URI
0247 a https://doi.org/10.1056/NEJMoa08050022 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-811622 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1175671802 URI
040 a (SwePub)gud (SwePub)orud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Sacco, R. L.u Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United States,McMaster University, Hamilton, ON, Canada4 aut
2451 0a Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
264 1a Boston :b Massachusetts medical society,c 2008
520 a BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. RESULTS: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.)
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Allmänmedicin0 (SwePub)302242 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex General Practice0 (SwePub)302242 hsv//eng
653 a Aged
653 a Angiotensin-Converting Enzyme Inhibitors/therapeutic use
653 a Aspirin/*administration & dosage/adverse effects
653 a Benzimidazoles/therapeutic use
653 a Benzoates/therapeutic use
653 a Brain Ischemia/epidemiology/prevention & control
653 a Delayed-Action Preparations
653 a Dipyridamole/adverse effects/*therapeutic use
653 a Double-Blind Method
653 a Drug Therapy
653 a Combination
653 a Factor Analysis
653 a Statistical
653 a Female
653 a Hemorrhage/chemically induced
653 a Humans
653 a Kaplan-Meiers Estimate
653 a Male
653 a Middle Aged
653 a Myocardial Infarction/epidemiology
653 a Platelet Aggregation Inhibitors/administration & dosage/adverse
653 a effects/*therapeutic use
653 a Proportional Hazards Models
653 a Recurrence/prevention & control
653 a Risk
653 a Stroke/*drug therapy/epidemiology/prevention & control
653 a Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
653 a Vascular Diseases/mortality
7001 a Diener, H. C.u University of Duisberg-Essen, Essen, Germany4 aut
7001 a Yusuf, S.u McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada4 aut
7001 a Cotton, D.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut
7001 a Ounpuu, S.u Boehringer Ingelheim, Burlington, ON, Canada4 aut
7001 a Lawton, W. A.u Boehringer Ingelheim, Bracknell, United Kingdom4 aut
7001 a Palesch, Y.u Medical University of Soudi Carolina, Charleston, United States4 aut
7001 a Martin, R. H.u Medical University of Soudi Carolina, Charleston, United States,Boehringer Ingelheim, Stockholm, Sweden4 aut
7001 a Albers, G. W.u Stanford University, Medical Center, Palo Alto, CA, United States4 aut
7001 a Bath, P.u University of Nottingham, Nottingham, United Kingdom4 aut
7001 a Bornstein, N.u Ichilov Medical Center, Tel Aviv, Israel4 aut
7001 a Chan, B. P.u National University Hospital, Singapore, Singapore,St. Johns's Medical College, Bangalore, India4 aut
7001 a Chen, S. T.u Chang Gung Memorial Hospital, Tapei, Taiwan4 aut
7001 a Cunha, L.u Hospitais da Universidade de Coimbra, Coimbra, Portugal4 aut
7001 a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine,Sahlgrenska University Hospital-Östra, Göteborg, Sweden4 aut0 (Swepub:gu)xdahbj
7001 a De Keyser, J.u University Medical Center Groningen, Groningen, Netherlands4 aut
7001 a Donnan, G. A.u University of Melbourne, Heidelberg West, Australia4 aut
7001 a Estol, C.u Neurological Center for Treatment and Research, Buenos Aires, Argentina4 aut
7001 a Gorelick, P.u University of Illinois, Chicago, United States4 aut
7001 a Gu, V.u Boehringer Ingelheim Shanghai Pharmaceuticals, Shanghai, China4 aut
7001 a Hermansson, K.4 aut
7001 a Hilbrich, L.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut
7001 a Kaste, M.u Helsinki University, Central Hospital, Helsinki, Finland4 aut
7001 a Lu, C.u Huashan Hospital, Shanghai, China4 aut
7001 a Machnig, T.u Boehringer Ingelheim, Ingelheim, Germany4 aut
7001 a Pais, P.4 aut
7001 a Roberts, R.4 aut
7001 a Skvortsova, V.u Russian State Medical University, Moscow, Russian Federation4 aut
7001 a Teal, P.u University of British Columbia, Vancouver, Canada4 aut
7001 a Toni, D.u University La Sapienza, Rome, Italy4 aut
7001 a VanderMaelen, C.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut
7001 a Voigt, T.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut
7001 a Weber, M.u SUNY Downstate College of Medicine, New York, United States4 aut
7001 a Yoon, B. W.u Seoul National University Hospital, Seoul, South Korea4 aut
7001 a von Euler, Mia,d 1967-
7102 a Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United Statesb McMaster University, Hamilton, ON, Canada4 org
7730 t New England Journal of Medicined Boston : Massachusetts medical societyg 359:12, s. 1238-51q 359:12<1238-51x 1533-4406x 0028-4793
8564 u https://doi.org/10.1056/NEJMoa0805002y Fulltext
8564 8u https://gup.ub.gu.se/publication/77923
8564 8u https://doi.org/10.1056/NEJMoa0805002
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81162
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:117567180

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy